Physician profile
Thomas Scioscia
NPI 1235177684
$274,381.67
in general payments reported to CMS, 2019-2025
13 companies · $23K in 2025
The $23K reported for 2025 was more than what 80% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59K · 2020: $50K · 2021: $47K · 2022: $31K · 2023: $34K · 2024: $30K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $87K · Food and Beverage: $88.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $87,090.65 |
| Food and Beverage | $88.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Choice Spine, LLC | $235,023.85 | 2019-2025 | Ambassador |
| Seaspine Orthopedics Corporation | $33,815.26 | 2019-2021 | |
| Ctl Medical Corporation | $4,000.00 | 2019 | |
| Republic Spine | $494.58 | 2019 | |
| Spinal Elements, INC. | $306.39 | 2019 | |
| Medtronic USA, INC. | $136.39 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $122.08 | 2019 | |
| Orthofix Medical, INC. | $119.36 | 2019 | |
| Centinel Spine, LLC | $117.20 | 2019 | |
| Boston Scientific Corporation | $88.41 | 2025 | Intracept |
| Cerapedics INC. | $62.07 | 2019 | |
| Si-Bone, INC. | $60.92 | 2021 | |
| Stability Biologics, LLC | $35.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Scioscia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.